Fuair foireann taighde ó Ionad Ailse Abramson (ACC) ag Scoil an Leighis Ollscoil Pennsylvania amach go bhfuil an meall te nó fuar arna chinneadh ag faisnéis leabaithe sna cealla ailse féin. “Hot” tumors are often considered more sensitive to immunotherapy. In a new study published this week in Immunity, the researchers explored the role of “tumor heterogeneity”, namely the ability of tumor cells to move, replicate, metastasize and respond to treatment. These new findings can help oncologists more accurately tailor the unique meall composition of patients.
Dúirt Ben Stanger, ollamh le gastraenterology agus bitheolaíocht chealla agus forbartha i Scoil an Leighis Ollscoil Pennsylvania Perelman, go bhfuil a mhéid a mheallann cealla T chuig siadaí á rialú ag na géinte a bhaineann go sonrach le meall. Ionas go bhfásfaidh siadaí, ní mór dóibh ionsaithe ón gcóras imdhíonachta a sheachaint. Tá dhá bhealach ann: forbairt a dhéanamh ina siadaí fuara, nó siadaí te ar féidir leo cealla T a ídiú, cealla meall a chosaint go héifeachtach ó dhamáiste do chóras imdhíonachta an othair.
In this study, researchers found that whether a tumor is hot or cold determines whether it will respond to immunotherapy. Cold tumor cells produce a compound called CXCL1, which can instruct bone marrow cells to enter the tumor, keep T cells away from the tumor, and ultimately make the immunotherapy insensitive. In contrast, knocking out CXCL1 in cold tumors promotes T cell infiltration and sensitivity to immunotherapy.
Ghin an fhoireann sraith línte cille a dhéanann aithris ar shaintréithe siadaí pancreatacha, lena n-áirítear na cineálacha cealla imdhíonachta atá iontu. Amach anseo, is féidir leis na línte cille meall seo cuidiú le cóireáil le haghaidh fo-chineálacha ar leith d’othair a bhfuil stáit ilchineálacht meall éagsúla acu a shainaithint agus a bharrfheabhsú.
